Locally advanced or metastatic non-small cell lung cancer
EMD Serono Canada, a division of EMD Inc.
Call for patient/clinician input open:
Call for patient/clinician input closed:
NOC Status at Filing:
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring METexon14 skipping alterations.
For the treatment of adult patients with locally advanced unresectable metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.